Consensus Innoviva, Inc.

Equities

INVA

US45781M1018

Real-time Estimate Cboe BZX Other stock markets 09:51:47 2024-05-20 am EDT			5-day change	1st Jan Change
16.16 ^USD	+1.16%		-1.08%	-0.16%

10:09am	Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	MT
May. 15	Transcript : Innoviva, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 09:20 AM

Evolution of the average Target Price on Innoviva, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4fd9d3ebb382aa.zScqzJGUyGJhe9ti_wsJaZ4Pm0QWqieDyfM22OtsZjY.mmYc9fWgkCBXLr1VnT1nB6x36hFJ5U3uvL1bu4AnUlGmRVKG89b-BwkeqA~9e06627806385aba635e00feb22a5608

Analyst Recommendations on Innoviva, Inc.

Morgan Stanley Adjusts Price Target on Innoviva to $10 From $13, Maintains Underweight Rating	23-03-03	MT
Morgan Stanley Adjusts Price Target on Innoviva to $14 From $13, Maintains Underweight Rating	22-10-13	MT
Goldman Sachs Starts Innoviva at Neutral With $16 Price Target	22-07-20	MT
Morgan Stanley Trims Innoviva's Price Target to $12 From $13, Underweight Rating Maintained	22-07-15	MT
Morgan Stanley Raises Innoviva's Price Target to $13 From $12, Maintains Underweight Rating	22-04-12	MT
Morgan Stanley Raises Innoviva's Price Target to $12 From $10, Maintains Underweight Rating	22-02-23	MT
INNOVIVA : Morgan Stanley Adjusts Innoviva PT to $10 From $8, Maintains Underweight Rating	20-11-11	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

15.98 USD

Average target price

16 USD

Spread / Average Target

+0.13%

High Price Target

16 USD

Spread / Highest target

+0.13%

Low Price Target

16 USD

Spread / Lowest Target

+0.13%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Innoviva, Inc.

Morgan Stanley
Goldman Sachs

Ratings for Innoviva, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Quarterly earnings - Rate of surprise

Company calendar